Drug Database
AL

albumin (albumin, Qiombiotec)

✓ Approved

Quimbiotec · Cell-based Therapies · Cell-based Therapies

What is albumin?

albumin is a cell-based therapies developed by Quimbiotec. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand Namesalbumin, Qiombiotec
CompanyQuimbiotec
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Quimbiotec

Therapeutic Indications

albumin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHypoalbuminaemia✓ Approved

Related Research Articles

PubMedIranian journal of pharmaceutical research : IJPR2026-09-20

Binding of Epimedium Flavonoids to Human Serum Albumin: Insights from Spectroscopic and Molecular Docking Studies.

Wang Na N, Wang Yuwei Y, Yang Yang Y, Dong Lele L et al.

Epimedin A (EA), epimedin B (EB), and epimedin C (EC), major bioactive flavonoids in Epimedium Herba, have diverse pharmacological activities; however, their interactions with human serum albumin (HSA) remain unclear. This study aimed to investigate the binding mechanisms of EA, EB, and EC to HSA. Multispectroscopic techniques, including UV-vis, fluorescence, and synchronous fluorescence spectroscopy, as well as molecular docking and dynamics simulations, were employed under simulated physiological conditions. Fluorescence spectra were recorded at 298, 303, and 310 K, and molecular docking was performed with HSA (PDB ID: 1BKE). All three flavonoids quenched the intrinsic fluorescence of HSA via static quenching, forming 1:1 complexes with binding constants greater than 104 L·mol-1 (EB > EA > EC at 298 K). Thermodynamic analysis indicated spontaneous binding driven by hydrogen bonds and van der Waals forces. Synchronous fluorescence showed no significant microenvironmental changes around Trp and Tyr residues. Molecular docking and dynamics simulations suggested ligand-dependent differences in the preferred binding regions of HSA. These findings provide preliminary in vitro evidence for the binding of epimedin flavonoids to HSA and may inform future pharmacokinetic investigations.

PMID 42763635
Read full article →
PubMedEsophagus : official journal of the Japan Esophageal Society2026-09-20

Long-term nutritional outcomes after esophagectomy following induction chemotherapy versus chemoradiotherapy for T4b esophageal cancer.

Sugimura Keijiro K, Tanaka Koji K, Sugase Takahito T, Momose Kota K et al.

The long-term impact of preoperative treatment on nutritional recovery after esophagectomy remains unclear. Although neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT) followed by surgery are established strategies for advanced esophageal cancer, their differential effects on postoperative weight loss have not been well characterized. This study aimed to compare long-term nutritional outcomes between esophagectomy after induction chemotherapy and after induction chemoradiotherapy in patients with T4b esophageal cancer. We retrospectively analyzed 86 patients with T4b esophageal cancer who underwent conversion surgery after induction treatment at six institutions between 2009 and 2021. Patients were categorized into a chemotherapy group (CT group, n = 51) and a chemoradiotherapy group (CRT group, n = 35). Longitudinal changes in body weight, lymphocyte counts, serum albumin levels, and prognostic nutritional index (PNI) were evaluated up to 24 months postoperatively. Postoperative weight loss was significantly greater in the CRT group than in the CT group, particularly at 9 and 12 months postoperatively (-13.4% vs. -9.6%, P = 0.011; -13.8% vs. -9.3%, P = 0.022). Weight loss persisted until 12 months after esophagectomy in the CRT group, whereas gradual recovery was observed after 6 months in the CT group. Lymphocyte counts were consistently lower in the CRT group from preoperation through 24 months postoperatively (all P < 0.05). Serum albumin levels did not differ significantly between groups. One year after surgery, deterioration in PNI was significantly greater in the CRT group (P < 0.001). Esophagectomy following induction chemoradiotherapy was associated with greater long-term weight loss and impaired nutritional recovery compared with surgery following chemotherapy alone. These findings highlight the need for intensified nutritional surveillance and intervention in patients treated with preoperative CRT.

PMID 42763385
Read full article →
PubMedJournal of research in nursing : JRN2026-09-20

Assessment of nutritional risk and associated determinants in adult intensive care unit patients: a prospective longitudinal observational study comparing NRS-2002 and mNUTRIC.

Gümüşkaşık İdris İ, Vural Fatma F, Özer Özlü Nazife Gamze NG

Malnutrition is common in critically ill patients and increases morbidity and mortality. Nutritional assessment is a fundamental component of nursing care; therefore, early identification of nutritional risk is essential for timely interventions in intensive care units (ICUs). This study evaluated nutritional risk in adult ICU patients, identified associated clinical and biochemical factors and compared the applicability of Nutritional Risk Screening 2002 (NRS-2002) and modified Nutrition Risk in the Critically Ill (mNUTRIC) scoring systems. This prospective longitudinal observational study was conducted in an adult ICU. Nutritional risk was assessed within 24-48 hours of admission and on day seven using NRS-2002 and mNUTRIC. Clinical, nutritional and biochemical variables were analysed using inferential and multivariate statistical methods. A total of 300 patients were included. According to NRS-2002, 87.7% and 83.7% of patients were at nutritional risk at the first and second assessments, respectively, whereas 57.0% and 59.7% were classified as low risk by mNUTRIC. NRS-2002 scores remained stable over time (p > 0.05), whereas mNUTRIC scores decreased significantly (p < 0.05). Age, caloric intake, C-reactive protein, albumin, haematocrit and blood glucose were significant predictors of nutritional risk, and both tools correlated positively with age. Nutritional risk is common among ICU patients. Both NRS-2002 and mNUTRIC identified patients at nutritional risk; however, mNUTRIC assessment reflected changes in disease severity and clinical status during ICU follow-up. These findings highlight the importance of routine nurse-led nutritional risk assessment to support early nutritional interventions and optimise patient care in the ICU.

PMID 42763484
Read full article →
PubMedRSC advances2026-09-19

A human serum albumin-assisted caged fluorophore probe for fluorescence turn-on detection of hypochlorous acid.

Kim Hyun Seo HS, Han Min Su MS

Fluorescence detection of hypochlorous acid (HOCl), a reactive oxidant that modulates immune responses and inflammation, can be complicated in serum due to nonspecific interactions between fluorescent probes and serum proteins. In particular, human serum albumin (HSA), the most abundant protein in serum, can alter the probe fluorescence by increasing background signals and distorting analyte-dependent responses. Rather than suppressing this protein-induced effect, we sought to convert albumin binding into a controlled signal-generation step. Here, we report DSH, an HSA-assisted caged fluorophore probe for HOCl detection in albumin-containing media. DSH was constructed by masking dansyl-sarcosine (DS) with a 2,4-dinitrophenyl caging group through a hydrazine-based linker that undergoes oxidative cleavage in response to HOCl. In the caged state, fluorescence is suppressed, and direct albumin-induced activation is minimised. Upon exposure to HOCl, oxidative cleavage of the linker releases DS, which subsequently binds to HSA and produces a fluorescence turn-on response. Thus, HSA binding, typically considered a source of matrix interference, is repurposed as a signal-amplifying step in the sensing mechanism. This DSH-based sensing strategy enables calibration-based quantitative detection of HOCl in phosphate-buffered saline supplemented with HSA and diluted human serum, supporting the feasibility of this caged-fluorophore design under controlled albumin-containing conditions.

PMID 42761357
Read full article →
PubMedCancer medicine2026-09-19

Preoperative Glucose-to-Albumin Ratio as a Prognostic Marker for Survival in Pancreatic Cancer Patients Undergoing Pancreatectomy.

Feci Andrea A, Lavine Isabel I, Shah Sophia S, Kraft Matthew M et al.

Pancreatic cancer (PC) disrupts metabolic and nutritional processes, including glucose homeostasis and albumin levels. Both hyperglycemia and hypoalbuminemia have been linked to poorer outcomes in various cancers, including PC. This study investigates the preoperative glucose-to-albumin ratio (GAR) as a potential prognostic marker of overall survival in patients undergoing pancreatic resection for pancreatic ductal adenocarcinoma (PDAC). This single-center retrospective analysis included patients who underwent curative-intent pancreatectomy for PDAC and adenosquamous carcinoma of the pancreas between 2017 and 2024. GAR was calculated from preoperative laboratory tests. Kaplan-Meier and Cox regression analyses were performed for recurrence-free and overall survival. A total of 566 patients were included (51% males and 49% females, mean age 68.3); 548 had PDAC and 18 had adenosquamous carcinoma of the pancreas. High GAR was associated with elevated CA 19-9, CEA and BMI (p < 0.0001, p < 0.0001, p = 0.02, respectively), more advanced T staging (p = 0.001), increased tumor size (p = 0.007), and AJCC staging (p = 0.04), as well as perineural invasion (p = 0.01) and lymphovascular invasion (p = 0.008). Kaplan-Meier analysis demonstrated significantly worse overall survival in high GAR patients (26.6 vs. 35.0 months, p = 0.004), while low albumin was associated with significantly worse recurrence-free survival (15.5 vs. 20.7 months, p = 0.04). Cox regression identified high GAR (HR = 1.3, p = 0.04), lower BMI (Body Mass Index) (p = 0.02), higher CA 19-9 (p = 0.006), N staging (p = 0.002), histological tumor grading (p < 0.0001), neoadjuvant chemotherapy (p = 0.002) and perineural invasion (p = 0.03) as independent risk factors for poorer overall survival. Higher preoperative GAR is associated with more advanced disease at presentation and an adverse prognosis in patients with resected PC.

PMID 42760632
Read full article →
PubMedJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2026-09-19

Unveiling the in vivo fate of albumin-bound paclitaxel nanoparticles by UPLC-MS/MS based on free, protein bound, and total drug.

Miao Yu Y, Zhang Ning N, Zhang Guolei G, Ye Runyi R et al.

Paclitaxel (PTX) has poor water solubility. Traditional formulations requiring solubilizers can induce allergic reactions and disrupt pharmacokinetics. Albumin-bound PTX nanoparticles (PTX-Nab) provide a solvent-free nanodelivery system that enhances solubility and may enable receptor-mediated tumor targeting. Comprehensive studies comparing its systemic pharmacokinetics, particularly the dynamics of free versus total drug concentrations and excretion routes, are still lacking. This study established a sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method coupled with ultrafiltration to simultaneously quantify free, protein-bound, and total PTX in rats following intravenous administration of PTX-Nab and conventional PTX-injection. PTX-Nab profoundly altered the pharmacokinetic profile. Despite a double dose (10 mg/kg), it exhibited significantly lower dose-normalized initial concentration (C0/Dose) and systemic exposure (AUC/Dose) along with a longer elimination half-life (t1/2) than the injection group (5 mg/kg), indicating sustained drug release and prolonged circulation. Tissue distribution showed preferential accumulation of PTX-Nab in lung and spleen.  Excretion studies showed a change in the primary excretion route. Unlike the renal-excreted conventional injection, PTX-Nab enhanced fecal excretion (56.14% versus 16.50%). These findings elucidate how the albumin carrier reshapes the in vivo fate of PTX through sustained release, tissue targeting, and clearance redirection, providing crucial pharmacokinetic evidence for its clinical application and future nanocarrier development.

PMID 42762797
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about albumin